fluorodeoxyglucose f18 has been researched along with pramipexole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drevets, WC; Mah, L; Manji, HK; Nugent, AC; Singh, JB; Zarate, CA | 1 |
| Albert, NL; Bartenstein, P; Boetzel, K; Cumming, P; Deutschländer, A; Gildehaus, FJ; la Fougère, C; Xiong, G | 1 |
1 trial(s) available for fluorodeoxyglucose f18 and pramipexole
| Article | Year |
|---|---|
Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Benzothiazoles; Bipolar Disorder; Brain; Dopamine Agonists; Female; Fluorodeoxyglucose F18; Humans; Limbic System; Male; Placebos; Pramipexole; Prefrontal Cortex; Radiopharmaceuticals | 2011 |
1 other study(ies) available for fluorodeoxyglucose f18 and pramipexole
| Article | Year |
|---|---|
Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Topics: Aged; Benzamides; Benzothiazoles; Dopamine Agonists; Dopamine Antagonists; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pramipexole; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2016 |